Veradermics VDPHL01 Phase 2 trial positive; 22.7-23.3 hairs/cm² increase

Veradermics, Inc. announced positive topline data from its Phase 2 clinical trial, Study ‘207,’ evaluating VDPHL01 in females with mild-to-moderate pattern hair loss. The proprietary extended-release oral minoxidil formulation demonstrated significant hair growth, with an average increase of 22.7 to 23.3 hairs/cm² at Month 6, and 88.9% to 90.0% of participants reporting 'improved' or 'much improved' hair coverage. The drug was generally well-tolerated with no treatment-related serious adverse events, and showed rapid onset of activity as early as Month 2. These results strengthen conviction for the upcoming Phase 2/3 Study ‘306’ readout in 1H 2027, positioning VDPHL01 as a potential first FDA-approved oral treatment for female pattern hair loss.